查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837403

尿激酶市場按產品類型、劑型、應用、最終用戶和分銷管道分類－2025-2032年全球預測

Urokinase Market by Product Type, Form, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，尿激酶市場規模將達到 28.3 億美元，複合年成長率為 5.44%。

主要市場統計數據
基準年 2024 18.5億美元
預計年份：2025年 19.5億美元
預測年份：2032年 28.3億美元
複合年成長率 (%) 5.44%

簡明扼要地說明尿激酶的科學原理、最新生產方法及其臨床應用，幫助領導者從策略角度解讀這些見解。

尿激酶是一種至關重要的溶栓藥物，具有獨特的臨床特性，並在多種治療場景中發揮持久的效用。尿激酶最初來自人體，如今擴大透過重組生物技術生產，臨床醫生可將其作為輔助性治療和全身性治療藥物，用於治療危及生命的血栓事件。尿激酶的動態特性，以及不斷發展的生產管道，使其重新引起了臨床專家和生技藥品生產商的策略關注。

近年來，表現系統和製劑科學的技術進步拓展了產品領域，迫使相關人員重新思考供應鏈配置、監管策略和臨床定位。同時，醫療服務模式和通路的改變也使得人們更需要清楚地了解終端用戶的需求動態和採購偏好。

本導言概述了尿激酶的生化基礎，重點介紹了關鍵的生產方法，並將臨床應用置於現代治療管道中，從而為後續分析奠定了基礎。透過建立這一基準，本報告幫助決策者理解後續章節的內容，這些章節探討了結構性變化、關稅影響、市場細分洞察、區域動態、企業行為以及切實可行的建議。

在不斷變化的醫療保健環境中，尿激酶的研究、生產和臨床應用

尿激酶領域正受到相互關聯的技術、監管和臨床趨勢的重塑，這些趨勢正在加速產品創新和策略定位的調整。重組表達平台的進步降低了變異性並提高了可擴展性，使新參與企業和成熟的生技藥品企業能夠重新思考其生產佈局和成本結構。製劑的改進，特別是冷凍乾燥和穩定輔料的改進，也與此趨勢相呼應，透過提高儲存穩定性並簡化低溫運輸要求，拓寬了給藥途徑的範圍。

臨床上，不斷更新的指引和針對特定適應症的標靶溶栓治療證據日益增多，正在影響溶栓治療的使用模式，促使臨床醫師根據藥物動力學、給藥途徑和出血風險等因素選擇治療方法，而非僅依賴傳統偏好。同時，醫療保健系統日益重視門診病人和流動醫療模式，迫使生產者和經銷商調整包裝、給藥方式和服務內容，以滿足分散式醫療的需求。

監管機構的期望也正轉向更加關注重組生技藥品的可比性數據、加強藥物安全檢測以及生命週期證據的生成。這些轉變為尋求最佳化臨床應用、供應可靠性和商業性可行性的相關人員帶來了機會和挑戰。因此，企業必須使其臨床證據策略與生產投資和上市計畫保持一致，才能保持競爭力。

美國2025年實施的關稅對尿激酶相關人員的供應鏈、採購決策和商業策略的累積影響

2025年的關稅調整為全球生技藥品供應鏈引入了新的成本因素，迫使生產商和經銷商重新評估籌資策略和物流策略。對於依賴跨境採購原料、初級包裝和契約製造服務的公司而言，當務之急是重組供應商關係，並尋找能夠在保證品質的同時限制到岸成本成長的替代方案。這些貿易政策的變化對採購前置作業時間產生了連鎖反應，各企業紛紛調整訂單以減輕關稅波動的影響。

為此，一些公司優先考慮將關鍵製造流程轉移到國內或近岸地區，以更好地控制成本並法律規範。投資決策日益重視雙重籌資策略，並加強關鍵中間體的庫存緩衝，以降低關稅衝擊帶來的風險。同時，經銷商評估定價模式和合約條款，重新談判長期供應協議，以納入關稅減免條款或鎖定批量折扣，從而抵消關稅上漲的影響。

臨床醫生和醫療保健採購人員承擔了部分增加的成本以維持市場進入，並承受了轉型期的價格壓力。展望未來，採購團隊和製造商的供應負責人正在將關稅敏感性納入情境規劃，強調供應商多元化，並加強合約保護以降低未來政策波動帶來的風險。這些調整表明，貿易政策如何能夠促進尿激酶價值鏈的結構重組。

明確產品類型、配方、臨床用途、最終用戶和分銷管道等方面的細分洞察，以指導有針對性的策略舉措。

依產品類型分類，可發現兩大主要研發管道：一是人源生技藥品，其特點是應用歷史悠久且臨床應用廣泛；二是重組尿激酶，透過生物技術表達系統生產，可實現可控生產和規模化生產。對於重組尿激酶而言，大腸桿菌和哺乳動物細胞表現方式的差異會影響糖基化譜、免疫抗原性原性以及下游加工製程的複雜性等特性，進而影響監管申報和生產成本結構。

液體製劑和粉末製劑的差異對物流和給藥方式有著重要影響，粉末製劑通常採用冷凍乾燥工藝，簡化了儲存和運輸，並可在照護現場進行複溶。這些優缺點會影響醫院藥局的庫存決策以及分散給藥的可行性。

冠狀動脈繞道手術繞道手術和瓣膜置換術，需要產品具備支持術中應用和與手術方案相容的特性；而溶栓應用，包括急性心肌梗塞和肺動脈栓塞，則優先考慮快速的全身活性和可預測的動態。使臨床證據和標籤與這些不同的應用場景相匹配，對於產品的推廣至關重要。

終端使用者群體涵蓋門診手術中心、診斷中心、醫院和專科診所，每個群體都有其獨特的採購週期、儲存能力和臨床人員配置。因此，醫院藥局、線上銷售和零售藥局等分銷管道必須調整其商業和服務模式，以滿足機構採購需求、病患就醫需求和監管要求。整合這些細分市場有助於更精準地進行產品定位、通訊和營運規劃。

透過對美洲、歐洲、中東和非洲以及亞太地區需求促進因素、監管細微差別和供應動態的深入洞察，您可以更好地制定地域策略。

在美洲，醫療保健系統展現出高水準的臨床專業技術，並建立了完善的醫院體系，重視正式的採購合約和嚴格的支付方評估。該地區傾向於選擇具有強力臨床證據且易於被納入醫院處方箋的藥品，其物流能力通常也足以支持先進的低溫運輸運作。因此，優先考慮該地區的製造商往往會重視臨床試驗計畫和醫院合作策略，以確保其產品能夠被三級和四級醫療機構採用。

歐洲、中東和非洲在法律規範和採購行為方面存在差異。許多歐洲國家實行集中式衛生技術評估流程，要求提供比較臨床證據和藥物經濟學原理，而中東和非洲市場則可能更注重供應鏈的可靠性和市場競爭。在這些地區運作的製造商通常會採取差異化的打入市場策略，以平衡監管機構的嚴格要求與適應不同基礎設施能力的靈活分銷模式的需求。

在亞太地區，生技藥品生產能力的快速擴張和區域契約製造生產商數量的不斷成長正在重塑採購和成本考量。該地區的監管機構正在使生技藥品指南與國際標準接軌，鼓勵生產商投資於本地臨床合作和監管合規。此外，門診和專科護理在某些市場中日益重要的作用，也推動了對支持分散式給藥的製劑和包裝的需求。這些區域性動態的綜合影響，要求企業調整其監管、生產和銷售計劃，使其與當地醫療保健系統的優先事項和營運實際情況相符。

企業行為、合作模式和營運重點塑造了尿激酶相關人員之間的競爭動態。

活躍於尿激酶領域的公司正朝著幾個策略重點邁進，以實現差異化競爭。首先，它們高度重視生產的可靠性和合規性。各公司正投資建置符合GMP標準的生產能力、製程驗證和品質體系，以確保向機構投資者持續供應產品。其次，它們擴大利用與合約研發受託製造廠商、臨床研究網路和分銷專家的策略夥伴關係，以加快市場進入速度，同時控制資本風險。

第三，產品開發策略正在從漸進式配方改進（例如開發凍乾製劑以提高穩定性）轉向對重組表現系統的深度平台投資，以減少批次差異並提高下游產量。第四，商業性策略強調兩個互補管道：直接與醫院採購團隊合作，將產品納入藥品目錄；以及透過數位化管道支持病患就醫和向專科診所推廣教育推廣活動。

最後，各公司正優先考慮上市後證據的生成和藥物安全檢測，以滿足監管要求並增強臨床醫生的信心。這些營運和策略重點正在重塑競爭格局，使那些能夠整合高品質生產、強力的臨床證據和適應性強的商業模式，從而在各種醫療環境中提供一致服務的企業更具優勢。

為行業領導者提供切實可行的建議，以加強臨床和商業管道的供應鏈、循證策略和市場進入。

產業領導者應優先考慮供應鏈韌性，具體措施包括對關鍵原料實施雙源籌資策略，並評估關鍵製造流程的近岸外包方案。這些措施，結合加強庫存管理和情境規劃，可以降低外部政策變化和物流中斷帶來的風險。同時，投資模組化製造管治和可擴展的表達平台，可以加快產品上市速度，更好地控制成本，並提供更大的靈活性以滿足臨床需求。

從臨床和監管角度來看，企業應將產品開發與特定適應症證據的產生結合。這意味著要設計分別針對外科手術應用和全身溶栓適應症的檢測方法，並準備能夠預見重組產品可比性查詢的核准申報資料。此外，相關人員還應制定完善的核准後安全性和真實世界證據項目，以支持藥品目錄討論和與支付方的談判。

在商業性，透過配方和服務實現差異化至關重要。提供冷凍乾燥製劑、易於復溶的工具、專業的護理師培訓課程以及物流解決方案，可以使產品對機構買家和分散式醫療服務提供者更具吸引力。最後，透過與臨床網路、製造外包和分銷專家建立策略夥伴關係關係，可以在確保品質和合規性的同時，加速產品進入市場。這些綜合措施能夠幫助機構抓住臨床機遇，同時有效管控營運風險。

調查方法：描述用於確保為決策者提供嚴謹可靠見解的資料收集、檢驗和分析過程。

我們的分析整合了第一手和第二手研究資料，建構了可靠的依證。第一手研究包括對臨床醫生、醫院藥劑師、監管專家和供應鏈管理人員進行結構化訪談，以獲取關於臨床效用、採購實踐和生產限制的第一手觀點。這些訪談，以及與生技藥品生產和製劑研發相關專業人員舉行的專家圓桌會議和討論，檢驗了技術假設並明確了營運方面的權衡取捨。

二級研究，包括同行評審的科學文獻、監管指導文件、臨床實踐指南和公開的企業資料，建立了事實基準，並對從一級研究中得出的主題進行了交叉檢驗。採用數據三角測量技術來協調不同資訊來源之間的差異，並確定共識觀點。品質保證流程包括方法論審核、資訊來源可靠性檢查以及專家反覆同行評審，以確保解釋的準確性。

此分析方法結合了定性主題分析和定量流程圖繪製，旨在探索製造工作流程、低溫運輸依賴關係和分銷管道，從而識別薄弱環節和潛在機會。這種混合方法確保了結論和建議既基於實證觀察，也基於技術可行性。

對尿激酶領域臨床應用、生產韌性與商業性差異化策略要務的最終綜合分析

尿激酶兼具成熟的臨床效用和現代生技藥品創新，其生產製程選擇、製劑策略和實證實踐共同決定著商業性成果。投資於可靠合規的生產流程，並將臨床證據與特定的外科手術和溶栓應用案例相結合的相關人員，將更有利於獲得醫療機構的認可。同時，調整產品劑型和分銷模式以滿足門診和專科護理機構的需求，將有助於其獲得更廣泛的臨床應用。

貿易政策的轉變和區域監管的差異凸顯了供應鏈多元化和區域監管規劃的重要性。積極將關稅敏感性納入採購決策並建立策略性製造和分銷夥伴關係關係的企業，能夠降低營運風險並維持市場准入。最終，健全的品質系統、有針對性的臨床證據以及以客戶為中心的商業模式的結合，將決定哪些企業能夠成功地將科研成果轉化為持續的患者可及性和機構應用。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 整合靶向奈米顆粒遞送平台可提高尿激酶的穩定性並降低全身出血風險。
  • 潛在生物相似藥的出現將加劇已開發醫療保健市場的價格競爭。
  • 在加護病房中，尿激酶用於治療 COVID-19 相關肺血栓症形成屬於仿單標示外用藥。
  • 超音波輔助導管引導尿激酶輸注技術的進步可最大限度地減少劑量和出血併發症
  • 金磚國家擴大對尿激酶治療方法的監管核准範圍，有助於提高市場滲透率和患者可及性。
  • 開發凍乾製劑旨在延長保存期限並方便醫院的庫存管理

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 尿激酶市場依產品類型分類

  • 人類尿激酶
  • 重組尿激酶
    • 在大腸桿菌中表達
    • 哺乳動物細胞表達

9. 尿激酶市場依形式分類

  • 液體溶液
  • 粉末

第10章 尿激酶市場依應用領域分類

  • 心血管外科
    • 冠狀動脈繞道手術手術
    • 置換術
  • 溶栓治療
    • 急性心肌梗塞
    • 肺動脈栓塞

第11章 尿激酶市場（依最終用戶分類）

  • 門診手術中心
  • 診斷中心
  • 醫院
  • 專科診所

第12章 尿激酶市場（依分銷管道分類）

  • 醫院藥房
  • 線上銷售
  • 零售藥房

第13章 尿激酶市場區域分析

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 尿激酶市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國尿激酶市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Medac GmbH
    • Guangdong Techpool Bio-Pharmaceutical Co., Ltd.
    • Cerbios-Pharma SA
    • Hanways Chempharm
    • Kraeber & Co GmbH
    • Parchem Fine & Specialty Chemicals
    • Microbix Biosystems Inc.
    • Taj Pharmaceuticals Ltd.
    • Zydus
    • Wanhua Biochem
Product Code: MRR-0355054AC506

The Urokinase Market is projected to grow by USD 2.83 billion at a CAGR of 5.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.85 billion
Estimated Year [2025] USD 1.95 billion
Forecast Year [2032] USD 2.83 billion
CAGR (%) 5.44%

A concise orientation to urokinase science, contemporary manufacturing approaches, and clinical roles to prepare leaders for strategic interpretation of detailed insights

Urokinase remains a pivotal thrombolytic agent with a distinct clinical profile and enduring utility across diverse therapeutic contexts. Historically derived from human sources and increasingly produced through recombinant biotechnology, urokinase serves clinicians as both an intraoperative adjunct and a systemic therapy for life-threatening thrombotic events. Its pharmacodynamic characteristics, combined with evolving manufacturing pathways, make it a subject of renewed strategic interest among clinical leaders and biologics manufacturers alike.

Over recent years, technological advances in expression systems and formulation science have broadened the product landscape, prompting stakeholders to reassess supply chain configurations, regulatory strategies, and clinical positioning. Concurrently, shifts in healthcare delivery models and distribution channels have amplified the need for greater clarity around end-user demand dynamics and procurement preferences.

This introduction frames the subsequent analysis by outlining the biochemical rationale for urokinase use, clarifying the principal manufacturing modalities, and situating clinical applications within contemporary care pathways. By establishing this baseline, the report primes decision-makers to interpret downstream sections that explore structural shifts, tariff impacts, segmentation insights, regional dynamics, corporate behaviors, and practical recommendations.

Transformative shifts reshaping urokinase research, manufacturing, and clinical adoption in a changing healthcare environment

The urokinase landscape is being reshaped by interconnected technological, regulatory, and clinical trends that together accelerate product innovation and strategic repositioning. Advances in recombinant expression platforms have reduced variability and improved scalability, thereby enabling new entrants and incumbent biologics producers to revisit manufacturing footprints and cost structures. Parallel improvements in formulation-particularly lyophilization and stabilizing excipients-have expanded the practicable settings for administration by improving shelf stability and simplifying cold chain requirements.

On the clinical front, evolving guidelines and a growing evidence base for targeted thrombolysis in specific indications have influenced utilization patterns. This has encouraged clinicians to differentiate therapeutic choices based on pharmacokinetics, administration route, and bleeding risk profiles rather than relying solely on legacy preferences. Simultaneously, healthcare systems are emphasizing outpatient and ambulatory delivery models, pressuring manufacturers and distributors to adapt packaging, dosing formats, and service offerings to meet decentralized care needs.

Regulatory expectations are also shifting toward greater emphasis on comparability data for recombinant biologics, enhanced pharmacovigilance, and lifecycle evidence generation. These combined shifts create both opportunity and complexity for stakeholders seeking to optimize clinical adoption, supply reliability, and commercial viability. Consequently, organizations must coordinate clinical evidence strategies with manufacturing investments and market access planning to stay competitive.

Cumulative effects of U.S. tariffs introduced in 2025 on supply chains, sourcing decisions, and commercial strategies for urokinase stakeholders

The 2025 tariff adjustments introduced new cost vectors across global biologics supply chains, prompting manufacturers and distributors to reassess sourcing and logistics strategies. For entities relying on cross-border procurement of raw materials, primary packaging, or contract manufacturing services, the immediate response centered on reconfiguring vendor relationships and identifying alternatives that preserved quality while mitigating incremental landed costs. These trade policy changes produced a ripple effect in procurement lead times as organizations shifted orders to mitigate exposure to variable tariff bands.

In response, several organizations prioritized onshoring or nearshoring of critical manufacturing steps to gain greater control over cost predictability and regulatory oversight. Investment decisions increasingly emphasized dual-sourcing strategies and enhanced inventory buffers for key intermediates to reduce vulnerability to tariff-driven disruptions. At the same time, distributors evaluated pricing models and contracting terms; longer-term supply agreements were renegotiated to include tariff mitigation clauses or to lock in volume discounts that offset heightened duties.

Clinicians and institutional buyers experienced transitional pricing pressure as organizations absorbed portions of cost increases to preserve market access. Looking ahead, procurement teams and manufacturer supply planners are integrating tariff sensitivity into scenario planning, emphasizing supplier diversity, and strengthening contractual protections to limit exposure to future policy volatility. These adaptations collectively illustrate how trade policy can catalyze structural realignments across the urokinase value chain.

Defining segmentation insights across product type, formulation, clinical use, end users, and distribution channels to guide targeted strategic initiatives

Product type segmentation reveals two principal development pathways: biologics derived from human sources, characterized by historical use and established clinical familiarity, and recombinant urokinase produced through biotechnological expression systems that allow for controlled manufacturing and scalability. Within recombinant avenues, the divergence between Escherichia coli expression and mammalian cell expression informs attributes such as glycosylation profiles, immunogenicity considerations, and downstream processing complexity, which in turn influence regulatory dossiers and manufacturing cost structures.

Form-based differentiation between liquid solution and powder formulations has important implications for logistics and administration. Liquid solutions offer immediate readiness for use in acute settings but impose stricter cold chain and stability constraints, while powder formulations, typically lyophilized, can simplify storage and transport and enable reconstitution at point of care. These trade-offs affect hospital pharmacy inventory decisions and the feasibility of decentralized administration.

Application segmentation underscores distinct clinical pathways: cardiovascular surgery applications such as coronary artery bypass grafting and valve replacement require product attributes that support intraoperative use and compatibility with surgical protocols, whereas thrombolytic therapy applications, including acute myocardial infarction and pulmonary embolism, prioritize rapid systemic activity and predictable pharmacodynamics. Aligning clinical evidence and labeling to these differentiated use cases is essential for adoption.

End-user segmentation spans ambulatory surgical centers, diagnostic centers, hospitals, and specialty clinics, each with unique procurement cycles, storage capabilities, and clinical staffing profiles. Consequently, distribution channels including hospital pharmacy, online sales, and retail pharmacy must adapt commercial and service models to meet institutional purchasing terms, patient access needs, and regulatory requirements. Integrating these segmentation dimensions enables more precise product positioning, messaging, and operational planning.

Regional insights highlighting demand drivers, regulatory nuances, and supply dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific to steer geographic strategies

In the Americas, healthcare systems exhibit a high degree of clinical specialization and established hospital systems that emphasize formal procurement contracts and rigorous payer assessments. This region tends to favor products with robust clinical evidence and clear pathways for hospital formulary inclusion, and logistics capabilities typically support advanced cold chain operations. As a result, manufacturers prioritizing this geography often emphasize clinical study programs and hospital engagement strategies to secure uptake within tertiary and quaternary centers.

The Europe, Middle East & Africa corridor presents heterogeneous regulatory frameworks and purchasing behaviors. Many countries in Europe maintain centralized health technology assessment processes that demand comparative clinical evidence and pharmacoeconomic rationale, while markets in the Middle East and Africa may prioritize supply chain reliability and price competitiveness. Manufacturers operating here often adopt differentiated market entry strategies that reconcile stringent regulatory expectations with the need for flexible distribution models adapted to diverse infrastructure capabilities.

In the Asia-Pacific region, rapid capacity expansion in biologics manufacturing and an increasing number of regional contract manufacturers have reshaped sourcing and cost considerations. Regulatory authorities across this region are advancing biologics guidelines in line with international standards, prompting manufacturers to invest in local clinical collaborations and regulatory alignment. Furthermore, the growing role of ambulatory and specialty care delivery in certain markets has driven demand for formulations and packaging that support decentralized administration. Together, these regional dynamics require companies to calibrate regulatory, manufacturing, and commercial plans to local health system priorities and operational realities.

Corporate behaviors, partnership models, and operational priorities shaping competitive dynamics among urokinase stakeholders

Companies active in the urokinase domain are converging on several strategic priorities that drive competitive differentiation. First, there is a pronounced focus on manufacturing reliability and compliance; firms are investing in GMP-certified capacity, process validation, and quality systems to ensure uninterrupted supply to institutional buyers. Second, strategic partnerships with contract development and manufacturing organizations, clinical research networks, and distribution specialists are increasingly used to accelerate market entry while controlling capital exposure.

Third, product development strategies vary between incremental formulation improvements-such as developing lyophilized presentations for enhanced stability-and deeper platform investments in recombinant expression systems that reduce batch variability and improve downstream yields. Fourth, commercial approaches emphasize two complementary pathways: direct engagement with hospital procurement teams for formulary inclusion and digital channels to support patient access and educational outreach for specialty clinics.

Finally, companies are prioritizing post-market evidence generation and pharmacovigilance to satisfy regulatory expectations and to build clinician confidence. These operational and strategic priorities collectively shape competition by privileging organizations that can integrate high-quality manufacturing, compelling clinical evidence, and adaptive commercial models into coherent offers for diverse healthcare settings.

Actionable recommendations for industry leaders to strengthen supply chains, evidence strategies, and market access across clinical and commercial channels

Industry leaders should prioritize resilience in their supply chains by implementing dual-sourcing strategies for critical raw materials and by assessing nearshoring options for key manufacturing steps. Coupling these actions with expanded inventory governance and scenario planning will reduce exposure to external policy shifts and logistical disruptions. In parallel, investing in modular manufacturing technologies and scalable expression platforms can shorten time to product availability and improve cost control, enabling more flexible responses to clinical demand.

From a clinical and regulatory standpoint, organizations should align product development with indication-specific evidence generation. This means designing studies that address surgical use cases separately from systemic thrombolytic indications, and preparing regulatory dossiers that anticipate comparability queries for recombinant products. Stakeholders should also develop robust post-authorization safety and real-world evidence programs to support formulary discussions and payer negotiations.

Commercially, differentiating through formulation and service is critical: offering lyophilized formats, simplified reconstitution tools, specialized nurse training programs, and tailored logistics solutions will make products more attractive to both institutional buyers and decentralized care providers. Finally, pursue strategic partnerships across clinical networks, contract manufacturers, and distribution specialists to accelerate market access while maintaining quality and compliance. These integrated actions will position organizations to capture clinical opportunity while managing operational risk.

Research methodology explaining data collection, validation, and analytical processes used to ensure rigorous and credible insights for decision makers

The analysis synthesizes primary and secondary research streams to construct a robust evidence base. Primary research comprised structured interviews with clinicians, hospital pharmacists, regulatory specialists, and supply chain managers to capture first-hand perspectives on clinical utility, procurement practices, and manufacturing constraints. These interviews were augmented by expert roundtables and consultations with professionals involved in biologics manufacturing and formulation development to validate technical assumptions and to contextualize operational trade-offs.

Secondary research drew on peer-reviewed scientific literature, regulatory guidance documents, clinical practice guidelines, and publicly available corporate disclosures to establish baseline factual context and to cross-verify themes emerging from primary interviews. Data triangulation techniques were applied to reconcile differences between sources and to identify consensus viewpoints. Quality assurance processes included methodological audits, source reliability checks, and iterative peer review by subject matter experts to ensure interpretive integrity.

Analytical approaches combined qualitative thematic analysis with quantitative process mapping-examining manufacturing workflows, cold chain dependencies, and distribution pathways-to identify vulnerabilities and opportunities. This mixed-methods approach ensured that conclusions and recommendations are grounded in both empirical observation and technical feasibility.

Concluding synthesis that distills strategic imperatives for clinical adoption, manufacturing resiliency, and commercial differentiation in the urokinase arena

Urokinase sits at the intersection of established clinical utility and contemporary biologics innovation, creating a landscape where manufacturing choices, formulation strategies, and evidence programs jointly determine commercial outcomes. Stakeholders that invest in reliable, compliant manufacturing and that align clinical evidence to specific surgical and thrombolytic use cases will be better positioned to achieve institutional acceptance. At the same time, adapting product formats and distribution models to the needs of ambulatory and specialty care settings provides a pathway to broader clinical reach.

Trade policy shifts and regional regulatory heterogeneity underscore the importance of supply chain diversification and localized regulatory planning. Organizations that proactively integrate tariff sensitivity into sourcing decisions and that cultivate strategic partnerships for manufacturing and distribution will reduce operational risk and sustain access. Ultimately, the combination of robust quality systems, targeted clinical evidence, and customer-centric commercial models will determine which organizations successfully translate scientific potential into consistent patient access and institutional adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of targeted nanoparticle-delivery platforms to enhance urokinase stability and reduce systemic hemorrhage risk
  • 5.2. Emergence of biosimilar urokinase candidates intensifying price competition in developed healthcare markets
  • 5.3. Off-label utilization of urokinase for COVID-19-associated pulmonary microthrombosis management in critical care settings
  • 5.4. Advances in ultrasound-assisted catheter-directed urokinase delivery to minimize dosage and bleeding complications
  • 5.5. Expansion of regulatory approvals for urokinase therapies in BRICS nations driving market penetration and access
  • 5.6. Development of lyophilized urokinase formulations for improved shelf life and ease of hospital inventory management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urokinase Market, by Product Type

  • 8.1. Human Urokinase
  • 8.2. Recombinant Urokinase
    • 8.2.1. Escherichia Coli Expression
    • 8.2.2. Mammalian Cell Expression

9. Urokinase Market, by Form

  • 9.1. Liquid Solution
  • 9.2. Powder

10. Urokinase Market, by Application

  • 10.1. Cardiovascular Surgery
    • 10.1.1. Coronary Artery Bypass Grafting
    • 10.1.2. Valve Replacement
  • 10.2. Thrombolytic Therapy
    • 10.2.1. Acute Myocardial Infarction
    • 10.2.2. Pulmonary Embolism

11. Urokinase Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Urokinase Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Sales
  • 12.3. Retail Pharmacy

13. Urokinase Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Urokinase Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Urokinase Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Medac GmbH
    • 16.3.2. Guangdong Techpool Bio-Pharmaceutical Co., Ltd.
    • 16.3.3. Cerbios-Pharma SA
    • 16.3.4. Hanways Chempharm
    • 16.3.5. Kraeber & Co GmbH
    • 16.3.6. Parchem Fine & Specialty Chemicals
    • 16.3.7. Microbix Biosystems Inc.
    • 16.3.8. Taj Pharmaceuticals Ltd.
    • 16.3.9. Zydus
    • 16.3.10. Wanhua Biochem

LIST OF FIGURES

  • FIGURE 1. GLOBAL UROKINASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS UROKINASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL UROKINASE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. UROKINASE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. UROKINASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. UROKINASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL UROKINASE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL UROKINASE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL UROKINASE MARKET SIZE, BY HUMAN UROKINASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL UROKINASE MARKET SIZE, BY ESCHERICHIA COLI EXPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL UROKINASE MARKET SIZE, BY MAMMALIAN CELL EXPRESSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL UROKINASE MARKET SIZE, BY LIQUID SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL UROKINASE MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL UROKINASE MARKET SIZE, BY VALVE REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL UROKINASE MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL UROKINASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL UROKINASE MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL UROKINASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL UROKINASE MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL UROKINASE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS UROKINASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS UROKINASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL UROKINASE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL UROKINASE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. GCC UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GCC UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GCC UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. GCC UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. GCC UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 306. GCC UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 307. GCC UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 308. GCC UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 309. GCC UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 310. GCC UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 311. GCC UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 312. GCC UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 313. GCC UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. GCC UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. GCC UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. GCC UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. GCC UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. BRICS UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. BRICS UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 342. BRICS UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS UROKINASE MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS UROKINASE MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS UROKINASE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS UROKINASE MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS UROKINASE MARKET SIZE, BY THROMBOLYTIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS UROKINASE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 352. BRICS UROKINASE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 353. BRICS UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 354. BRICS UROKINASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 355. G7 UROKINASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 356. G7 UROKINASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 357. G7 UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 358. G7 UROKINASE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 359. G7 UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2018-2024 (USD MILLION)
  • TABLE 360. G7 UROKINASE MARKET SIZE, BY RECOMBINANT UROKINASE, 2025-2032 (USD MILLION)
  • TABLE 361. G7 UROKINASE MARKET SIZE, BY FORM, 20